ImmuPharma plc (AIM:IMM)
London · Delayed Price · Currency is GBP · Price in GBX 4.620
+0.220 (5.00%)
Jun 16, 2026, 10:15 AM GMT
ImmuPharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
27.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 118.35K | -8.32K | -6.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 49.66M |
| Palatin Technologies | 9.76M |
| IXICO | 7.28M |
| SkinBioTherapeutics | 5.23M |
| Arecor Therapeutics | 1.71M |
| Fusion Antibodies | 1.60M |
| Ondine Biomedical | 1.43M |
| Aptamer Group | 1.38M |
ImmuPharma News
- 20 days ago - ImmuPharma Annual report: H2 2025 - Filings
- 20 days ago - ImmuPharma Annual report: H2 2025 - Filings
- 3 months ago - ImmuPharma Transcript: Investor update - Transcripts
- 3 months ago - ImmuPharma Press release: Investor update - Filings
- 3 months ago - ImmuPharma Slides: Investor update - Filings
- 3 months ago - AIM Market Roundup: Tern, T42 IoT, Atlantic Lithium - The Armchair Trader
- 4 months ago - AIM Market Roundup: Immupharma, Pebble Beach, Tungsten West - The Armchair Trader
- 7 months ago - FTSE Flat as Wall Street Gains Fail to Inspire - Investomania